GR1007010B - Ινσουλινοειδη πεπτιδια - Google Patents

Ινσουλινοειδη πεπτιδια

Info

Publication number
GR1007010B
GR1007010B GR20090100545A GR20090100545A GR1007010B GR 1007010 B GR1007010 B GR 1007010B GR 20090100545 A GR20090100545 A GR 20090100545A GR 20090100545 A GR20090100545 A GR 20090100545A GR 1007010 B GR1007010 B GR 1007010B
Authority
GR
Greece
Prior art keywords
peptides
insulinoid
insulin peptides
chains
derivatives
Prior art date
Application number
GR20090100545A
Other languages
English (en)
Inventor
Κλεομενης Μπαρλος
Κωνσταντινος Μπαρλος
Original Assignee
Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras),
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), filed Critical Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras),
Priority to GR20090100545A priority Critical patent/GR1007010B/el
Publication of GR1007010B publication Critical patent/GR1007010B/el
Priority to PCT/GR2010/000045 priority patent/WO2011042762A2/en
Priority to US13/500,978 priority patent/US20120302498A1/en
Priority to CN201510987995.XA priority patent/CN105481974A/zh
Priority to CA2776995A priority patent/CA2776995C/en
Priority to CN201080053472.3A priority patent/CN102844328B/zh
Priority to EP10777093.5A priority patent/EP2486045B1/en
Priority to US14/711,494 priority patent/US10711053B2/en
Priority to HK16108698.0A priority patent/HK1220701A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)

Abstract

Περιγράφεται η παρακευή ινσουλινοειδών πεπτιδίων, χιμαιρικών ινσουλινοειδών πεπτιδίων και παραγώγων τους με τυχαίο συνδυασμό των αλυσίδων τους Α και Β και περιγραφή της εφαρμογής των προϊόντων που λαμβάνονται για θεραπευτικούς σκοπούς.
GR20090100545A 2009-10-08 2009-10-08 Ινσουλινοειδη πεπτιδια GR1007010B (el)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GR20090100545A GR1007010B (el) 2009-10-08 2009-10-08 Ινσουλινοειδη πεπτιδια
PCT/GR2010/000045 WO2011042762A2 (en) 2009-10-08 2010-10-08 Insulin like peptides
US13/500,978 US20120302498A1 (en) 2009-10-08 2010-10-08 Insulin like peptides
CN201510987995.XA CN105481974A (zh) 2009-10-08 2010-10-08 胰岛素样肽
CA2776995A CA2776995C (en) 2009-10-08 2010-10-08 Insulin like peptides
CN201080053472.3A CN102844328B (zh) 2009-10-08 2010-10-08 胰岛素样肽
EP10777093.5A EP2486045B1 (en) 2009-10-08 2010-10-08 Insulin like peptides
US14/711,494 US10711053B2 (en) 2009-10-08 2015-05-13 Insulin like peptides
HK16108698.0A HK1220701A1 (zh) 2009-10-08 2016-07-20 胰岛素样肽

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20090100545A GR1007010B (el) 2009-10-08 2009-10-08 Ινσουλινοειδη πεπτιδια

Publications (1)

Publication Number Publication Date
GR1007010B true GR1007010B (el) 2010-10-07

Family

ID=43708791

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20090100545A GR1007010B (el) 2009-10-08 2009-10-08 Ινσουλινοειδη πεπτιδια

Country Status (7)

Country Link
US (2) US20120302498A1 (el)
EP (1) EP2486045B1 (el)
CN (2) CN105481974A (el)
CA (1) CA2776995C (el)
GR (1) GR1007010B (el)
HK (1) HK1220701A1 (el)
WO (1) WO2011042762A2 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9434780B2 (en) 2011-08-04 2016-09-06 Relaxera Pharma Gmbh & Co. Kg I.G. Process for preparing human relaxin-2
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
CN104892748B (zh) * 2014-03-04 2018-12-21 深圳翰宇药业股份有限公司 人类松弛素-2衍生物以及由其制备人类松弛素-2的方法
CN105884879A (zh) * 2015-01-26 2016-08-24 漳州博欣生物技术有限公司 一种胰岛素类似物的化学合成方法
CN110234339A (zh) * 2016-09-06 2019-09-13 佩特雷化学和生物制药学实验室有限公司 胰岛素原衍生物
BR112019016139A2 (pt) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
JP2020138975A (ja) * 2020-05-18 2020-09-03 ケミカル アンド バイオファーマシューティカル ラボラトリーズ オブ パトラ エス．エー． 側鎖結合を介する固相ペプチド合成

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835251A (en) * 1986-06-23 1989-05-30 Genetech, Inc. Method of chain combination
HU230522B1 (hu) 1998-03-27 2016-10-28 Janssen Pharmaceutica N.V HIV-gátló pirimidinszármazékok
HU227453B1 (en) 1998-11-10 2011-06-28 Janssen Pharmaceutica Nv Hiv replication inhibiting pyrimidines, and pharmaceutical compositions containing them
ES2542326T3 (es) 2000-05-08 2015-08-04 Janssen Pharmaceutica Nv Inhibidores de la replicación del VIH
AP2081A (en) * 2004-06-18 2010-01-04 Ipf Pharmaceuticals Gmbh Oligomeric peptides and their use for the treatment of HIV infections
US7893197B2 (en) * 2004-08-25 2011-02-22 Janssen Pharmaceutica N.V. Relaxin-3 chimeric polypeptides and their preparation and use
ES2347815T3 (es) 2005-03-04 2010-11-04 Tibotec Pharmaceuticals 2-(4-cianofenil)-6-hidroxilaminopirimidinas inhibidoras de hiv.
WO2007093220A1 (en) * 2006-02-17 2007-08-23 Associazione Foresta Per La Ricerca Nella Riproduzione Umana Use of insulin-like factor 3 for treating osteoporosis and bone disorders
ES2624593T3 (es) 2006-12-06 2017-07-17 Janssen Sciences Ireland Uc Sal de hidrobromuro de un compuesto anti-VIH.
AU2007332654B2 (en) 2006-12-13 2013-06-20 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
GR1006941B (el) * 2009-06-01 2010-08-27 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Πεπτιδικη συνθεση (peptide synthesis)
US20110196156A1 (en) 2009-06-22 2011-08-11 Mukund Keshav Gurjar Process for synthesis of diarylpyrimidine non-nucleoside reverse transcriptase inhibitor
US8153790B2 (en) 2009-07-27 2012-04-10 Krizmanic Irena Process for the preparation and purification of etravirine and intermediates thereof

Also Published As

Publication number Publication date
HK1220701A1 (zh) 2017-05-12
WO2011042762A2 (en) 2011-04-14
CA2776995A1 (en) 2011-04-14
CN102844328A (zh) 2012-12-26
CN105481974A (zh) 2016-04-13
EP2486045B1 (en) 2018-08-22
CN102844328B (zh) 2016-01-20
US20120302498A1 (en) 2012-11-29
CA2776995C (en) 2019-04-09
WO2011042762A3 (en) 2011-06-16
EP2486045A2 (en) 2012-08-15
US10711053B2 (en) 2020-07-14
US20160009778A1 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
CY1122073T1 (el) Μορια αντισωματος που εχουν εξειδικευση για τον ανθρωπινο οχ40
CY1121431T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για τον ανθρωπινο οχ40
CY1123675T1 (el) Πολυαιθυλενογλυκολιωμενου φαρμακου-συνδετες για βελτιωμενες φαρμακοκινητικες προϊοντος συζευξης προσδετη-φαρμακου
CY1124024T1 (el) Νεες ctla4-ig ανοσοπροσκολλητινες
CY1122824T1 (el) Πρωτεϊνες συντηξης και εμβολια συνδυασμου
CY1117956T1 (el) N3-αντικατεστημενα-n1-sulfonyl-5-fluoropyrimidinone παραγωγα
CY1115254T1 (el) Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις
MA40278A (fr) Acides gras et leur utilisation dans la conjugaison de biomolécules
GR1007010B (el) Ινσουλινοειδη πεπτιδια
NZ703581A (en) Anti-cd70 antibody drug conjugates
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
CY1115595T1 (el) Αλατα ρασιγιλινης και φαρμακευτικη παρασκευη αυτων
CY1116192T1 (el) Πυρρολοβενζοδιαζεπινες και συζευγματα αυτων
MX2017008215A (es) Conjugados de farmacos proteinas de union que comprenden derivados de antraciclina.
BRPI0906611A2 (pt) Produtos implantáveis compreendendo nanopartículas.
MX2019012201A (es) Conjugados enlazadores auto-estabilizantes.
BR112012028737A2 (pt) embalagens de produtos farmacêuticos, particularmente produtos parenterais
CY1114458T1 (el) Πυρρολοβενζοδιαζεπινες και προϊοντα συζευξης αυτων
HUE049325T2 (hu) Stabilitás modulátor linker antitest-hatóanyag konjugátumokhoz történõ alkalmazásra
CY1120460T1 (el) Παραγωγο πυραζολοπυριμιδινης με υποκατεστημενη τη θεση 4, και χρηση αυτου στην παρασκευη φαρμακων
BR112013019913A2 (pt) derivados de benzodiazepina citotóxicos.
CR20110002S (es) Barra de chocolate
CY1116803T1 (el) Φαρμακευτικος συνδυασμος για χρηση στον γλυκαιμικο ελεγχο σε ασθενεις με διαβητη τυπου 2
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης

Legal Events

Date Code Title Description
PG Patent granted